Recurrent Urinary Tract Infection Clinical Trial
Official title:
Gag Therapy for Recurrent Urinary Tract Infection Assessing Comparability to International Nitrofurantoin Gold Standard Study
The GT RACING is a study comparing the efficacy of HA-CS bladder installations with prophylactic antibiotics in the prevention of recurrent urinary tract infections (rUTI).
The main objective of the study is to compare efficacy between hyaluronic acid - chondroitin sulphate (HA-CS) treatment and gold standard treatment (AB prophylaxis). Study is set-up as non-inferiority, parallel group trial, with a 1:1 randomization. Study population: Female (>18rs) with at least 3 symptomatic urinary tract infections (UTI's) in the previous year with no adequate curable therapeutic options. Intervention: Intervention group (n=50): 50ml of sterile Ialuril (HA 1.6% CS 2%) weekly for 6 weeks, followed by monthly maintenance therapy for 1 year. Control group (n=50): oral nitrofurantoin 100mg daily (1dd100mg or 2dd50mg) for 1 year. In case of resistance/intolerance/allergy for nitrofurantoin alternatively trimethoprim 100mg daily will be given. During the study patients will fill-out questionnaires regarding symptoms, quality of life and use of healthcare. Furthermore urine will be collected at set timepoints. Main study parameters/endpoints: The main study parameter is the number of UTI per patient-year. Secondary parameters are time to rUTI (wks.), outcome on the global responce assessment (GRA) scale, pattern of antibiotic resistance, outcome on the patient reported outcome questionnaire, cost effectiveness and Quality-of-life. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02357758 -
Effects of Antibiotic Prophylaxis on Recurrent UTI in Children
|
Phase 4 | |
| Completed |
NCT04306731 -
Effect of Nanotechnology Structured Water Magnalife for the Prevention of Recurrent Urinary Tract Infections.
|
N/A | |
| Recruiting |
NCT05553652 -
The Effect of ASTARTE™ on Recurrent Urinary Tract Infection
|
N/A | |
| Completed |
NCT01958073 -
Vaginal Estrogen for the Prevention of Recurrent Urinary Tract Infection in Postmenopausal Women
|
Phase 4 | |
| Recruiting |
NCT06124820 -
RCT Comparing Intravaginal Laser Therapy to Sham in Post-menopausal Women With Recurrent Urinary Tract Infections
|
N/A | |
| Recruiting |
NCT04807894 -
Prevention of Recurrent UTI Using Vaginal Testosterone Versus Placebo Placebo
|
Phase 4 | |
| Enrolling by invitation |
NCT04077580 -
The Effect of Methenamine Hippurate to Reduce Antibiotic Prescribing in Elderly Women With Recurrent UTI
|
Phase 4 | |
| Terminated |
NCT03143920 -
Hyperbaric Oxygen Therapy for Inflammatory Conditions of the Urinary Bladder
|
Early Phase 1 | |
| Recruiting |
NCT04859621 -
Phase II Clinical Trial of Vitamin D3 for Reducing Recurrence of Recurrent Lower Urinary Tract Infections
|
Phase 2 | |
| Recruiting |
NCT04831840 -
Recurrent Urinary Tract Infections and the Microbiome
|
||
| Withdrawn |
NCT03854396 -
Clinical Trial on the Preventive Effect of Intravaginal Prasterone on Recurrent Urinary Tract Infections in Postmenopausal Women
|
Phase 3 | |
| Completed |
NCT02705495 -
Acupuncture for Prevention of Recurrent Urinary Tract Infections.
|
N/A | |
| Active, not recruiting |
NCT05537519 -
Phage Therapy for the Treatment of Urinary Tract Infection
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06035601 -
EHR-integrated rUTI Texting Platform
|
N/A | |
| Not yet recruiting |
NCT04285320 -
Antibiotic Bladder Instillations vs. Oral Suppression for the Treatment of Recurrent Urinary Tract Infections
|
Phase 4 | |
| Recruiting |
NCT03142295 -
Controlled Human Urine Transfusion for UTI
|
N/A | |
| Recruiting |
NCT05895578 -
Effect of a Probiotic on the Urinary Tract Microbiota of Participants With Recurrent Urinary Tract Infection.
|
N/A | |
| Completed |
NCT00214045 -
Rigid Versus Flexible Cystoscopy in Women
|
N/A | |
| Enrolling by invitation |
NCT05551949 -
Preventing Recurrent UTI With Vaginal Estrogen
|
Phase 4 | |
| Recruiting |
NCT05472779 -
Periurethral vs Intravaginal Estrogen for Prevention of Recurrent Urinary Tract Infections
|
Phase 2 |